C4 Therapeutics (CCCC) Depreciation & Amortization (CF) (2019 - 2026)

C4 Therapeutics' Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $404000.0 for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 11.4% year-over-year to $404000.0 in Q1 2026; TTM through Mar 2026 was $1.9 million, a 4.44% increase from a year earlier, with the FY2025 full-year figure at $2.0 million, up 7.76% from the prior year.
• Depreciation & Amortization (CF) declined to $404000.0 in Q1 2026 per CCCC's latest filing, from $428000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $615000.0 in Q2 2025 and bottomed at $305000.0 in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $448000.0 (2024), against an average of $455117.6.
• Across the five-year window, Depreciation & Amortization (CF) sank 32.37% in 2022 and surged 78.69% in 2023, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $521000.0 in 2022, then declined by 17.47% to $430000.0 in 2023, then gained by 11.63% to $480000.0 in 2024, then retreated by 10.83% to $428000.0 in 2025, then decreased by 5.61% to $404000.0 in 2026.
• Per Business Quant, the three latest CCCC Depreciation & Amortization (CF) figures stand at $404000.0 (Q1 2026), $428000.0 (Q4 2025), and $460000.0 (Q3 2025).